SGLT2 inhibitors, originally developed for type 2 diabetes, have shown cardioprotective effects in patients with and without diabetes, particularly in heart failure. Recent research suggests they may also have anticancer properties, making them a promising option in cardio-oncology. These inhibitors protect against cardiovascular toxicity caused by cancer treatments through various mechanisms, including anti-inflammatory, antioxidant, and autophagy-enhancing effects. They also show potential in reducing cancer progression by inhibiting pathways involved in tumor growth and survival. Preclinical studies indicate that SGLT2 inhibitors can mitigate the cardiotoxic effects of chemotherapy and radiotherapy, while clinical trials support their use in patients with cancer. However, more research is needed to confirm their efficacy and safety in this context. The dual role of SGLT2 inhibitors in both cardioprotection and anticancer therapy highlights their potential in improving outcomes for cancer patients.SGLT2 inhibitors, originally developed for type 2 diabetes, have shown cardioprotective effects in patients with and without diabetes, particularly in heart failure. Recent research suggests they may also have anticancer properties, making them a promising option in cardio-oncology. These inhibitors protect against cardiovascular toxicity caused by cancer treatments through various mechanisms, including anti-inflammatory, antioxidant, and autophagy-enhancing effects. They also show potential in reducing cancer progression by inhibiting pathways involved in tumor growth and survival. Preclinical studies indicate that SGLT2 inhibitors can mitigate the cardiotoxic effects of chemotherapy and radiotherapy, while clinical trials support their use in patients with cancer. However, more research is needed to confirm their efficacy and safety in this context. The dual role of SGLT2 inhibitors in both cardioprotection and anticancer therapy highlights their potential in improving outcomes for cancer patients.